LMNL News and Press, Liminal Biosciences Inc From 11/08/22

Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022 Canada NewsWire LAVAL, QC and CAMBRIDGE, England , Nov. 8, 2022 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company")...

Liminal BioSciences ( NASDAQ: LMNL ) received approval from the Qualifications Department of The Nasdaq Stock Market to transfer its common shares from the Nasdaq Global Market to the Nasdaq Capital Market. The Canadian company said its shares will begin trading on the...

Liminal BioSciences Announces Listing Transfer to Nasdaq Capital Market Canada NewsWire LAVAL, QC and CAMBRIDGE, England , Sept. 1, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that...

Liminal Biosciences to Present at H.C. Wainwright 24th Annual Global Investment Conference Canada NewsWire LAVAL, QC and CAMBRIDGE, England , Aug. 29, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a dev...

Canadian biotech Liminal BioSciences ( NASDAQ: LMNL ) announced Thursday that the company terminated the long-term legacy CDMO agreement relating to its previously owned plasma-derived therapeutics business in favor of ~$33.1M cash savings. The deal signed in May 2021 incl...

Liminal BioSciences Announces Termination of Legacy CDMO Contract Canada NewsWire Termination results in anticipated cash savings of $33.1 million Removes last of legacy contracts associated with former plasma-derived therapeutics business LAV...

Liminal BioSciences press release ( NASDAQ: LMNL ): Q2 Net loss from continuing operations of $6.5M vs. $12.6M prior year quarter. Cash and cash equivalents were $55.8 million at June 30, 2022 while our working capital, i.e., the current assets net of current liabilities, ...

Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights Canada NewsWire $55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras development Net loss from continuing operations of $...

Liminal BioSciences ( NASDAQ: LMNL ) said Thursday it discontinued development of fezagepras . The decision is based on results from the phase 1a single ascending dose clinical trial, which showed that fezagepras was significantly inferior to sodium phenylbutyrate as a nit...

Liminal BioSciences Announces Discontinuation of Fezagepras Development Canada NewsWire LAVAL, QC and CAMBRIDGE, England , July 21, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it h...